Analyses of lymphocyte tumor recruitment across treatment groups recapitulate our earlier observation, with combination therapy yielding a significant increase in total infiltrating CD8 T lymphocytes (Fig. 5g), identified using the gene expression markers Cd3d, CD8a, Cd8b1 as previously described31. The gene discussed is CD3D; the disease is neoplasm.